MedTrace Logo

Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study

NCT05074706 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2023-01-25

No results posted yet for this study

Summary

The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion

Conditions

Interventions

BIOLOGICAL

IgG antibodies to Sars-Cov-2

Samples will be collected between 30 and 60 days after second vaccine dose.

BIOLOGICAL

QuantiFERON SARS-CoV-2 test

Samples will be collected within 9 months after completion of the vaccination series

Sponsors & Collaborators

  • San Gerardo Hospital

    collaborator OTHER

  • University of Milano Bicocca

    lead OTHER

Principal Investigators

  • Carlo Gambacorti Passerini, Professor · San Gerardo Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-09
Primary Completion
2022-06-15
Completion
2022-06-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05074706 on ClinicalTrials.gov